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Abstract. This review further clariﬁes the concept of pharmaceutical quality by design (QbD) and describes
its objectives. QbD elements include the following: (1) a quality target product proﬁle (QTPP) that identiﬁes
the critical quality attributes (CQAs) of the drug product; (2) product design and understanding including
identiﬁcation of critical material attributes (CMAs); (3) process design and understanding including
identiﬁcation of critical process parameters (CPPs), linking CMAs and CPPs to CQAs; (4) a control strategy
that includes speciﬁcations for the drug substance(s), excipient(s), and drug product as well as controls for
each step of themanufacturing process; and (5) process capability and continual improvement.QbD tools and
studies include prior knowledge, risk assessment, mechanistic models, design of experiments (DoE) and data
analysis, and process analytical technology (PAT). As the pharmaceutical industry moves toward the
implementation of pharmaceutical QbD, a common terminology, understanding of concepts and expectations
are necessary. This understanding will facilitate better communication between those involved in risk-based
drug development and drug application review.
KEY WORDS: control strategy; critical quality attributes; pharmaceutical quality by design; process
understanding; product understanding.
INTRODUCTION
Quality by design (QbD) is a concept ﬁrst developed by the
quality pioneer Dr. JosephM. Juran (1). Dr. Juran believed that
quality should be designed into a product, and that most quality
crises and problems relate to the way in which a product was
designed in the ﬁrst place. Woodcock (2) deﬁned a high-quality
drug product as a product free of contamination and reliably
delivering the therapeutic beneﬁt promised in the label to the
consumer. The US Food and Drug Administration (FDA)
encourages risk-based approaches and the adoption of QbD
principles in drug product development, manufacturing, and
regulation. FDA’s emphasis onQbD began with the recognition
that increased testing does not necessarily improve product
quality. Quality must be built into the product.
Over the years, pharmaceutical QbD has evolved with the
issuance of ICH Q8 (R2) (Pharmaceutical Development), ICH
Q9 (Quality RiskManagement), and ICHQ10 (Pharmaceutical
Quality System) (3–5). In addition, the ICH Q1WG on Q8, Q9,
andQ10Questions and Answers; the ICHQ8/Q9/Q10 Points to
Consider document; and ICH Q11 (Development and Manu-
facture of Drug Substance) have been issued, as have the
conclusions of FDA-EMA’s parallel assessment of Quality-By-
Design elements of marketing applications (6–9). These docu-
ments provide high level directions with respect to the scope and
deﬁnition of QbD as it applies to the pharmaceutical industry.
Nonetheless, many implementation details are not
discussed in these guidances or documents. There is confusion
among industry scientists, academicians, and regulators despite
recent publications (10–13). This paper is intended to describe
the objectives of pharmaceutical QbD, detail its concept and
elements, and explain implementation tools and studies.
PHARMACEUTICAL QUALITY BY DESIGN
OBJECTIVES
Pharmaceutical QbD is a systematic approach to devel-
opment that begins with predeﬁned objectives and empha-
sizes product and process understanding and control based on
sound science and quality risk management (3). The goals of
pharmaceutical QbD may include the following:
1. To achieve meaningful product quality speciﬁcations
that are based on clinical performance
2. To increase process capability and reduce product
variability and defects by enhancing product and
process design, understanding, and control
3. To increase product development and manufacturing
efﬁciencies
4. To enhance root cause analysis and postapproval
change management
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Under QbD, these goals can often be achieved by
linking product quality to the desired clinical performance
and then designing a robust formulation and manufactur-
ing process to consistently deliver the desired product
quality.
Since the initiation of pharmaceutical QbD, the FDA
has made signiﬁcant progress in achieving the ﬁrst
objective: performance-based quality speciﬁcations. Some
examples of FDA policies include tablet scoring and bead
sizes in capsules labeled for sprinkle (14,15). The recent
FDA discussions on the assayed potency limits for narrow
therapeutic index drugs and physical attributes of generic
drug products reﬂect this trend (16). Nonetheless, it
should be recognized that ICH documents (3–9) did not
explicitly acknowledge clinical performance-based speciﬁ-
cations as a QbD goal, although this was recognized in a
recent scientiﬁc paper (10).
The second objective of pharmaceutical QbD is to
increase process capability and reduce product variability
that often leads to product defects, rejections, and recalls.
Achieving this objective requires robustly designed prod-
uct and process. In addition, an improved product and
process understanding can facilitate the identiﬁcation and
control of factors inﬂuencing the drug product quality.
After regulatory approval, effort should continue to
improve the process to reduce product variability, defects,
rejections, and recalls.
QbD uses a systematic approach to product design and
development. As such, it enhances development capability,
speed, and formulation design. Furthermore, it transfers
resources from a downstream corrective mode to an
upstream proactive mode. It enhances the manufacturer’s
ability to identify the root causes of manufacturing
failures. Hence, increasing product development and
manufacturing efﬁciencies is the third objective of phar-
maceutical QbD.
The ﬁnal objective of QbD is to enhance root cause
analysis and postapproval change management. Without good
product and process understanding, the ability to efﬁciently
scale-up and conduct root cause analysis is limited and
requires the generation of additional data sets on the
proposed larger scale. FDA’s change guidances (17,18)
provide a framework for postapproval changes. Recently,
the FDA issued a guidance intended to reduce the regulatory
ﬁling requirements for speciﬁc low-risk chemistry,
manufacturing, and control (CMC) postapproval manufactur-
ing changes (19).
ELEMENTS OF PHARMACEUTICAL QUALITY
BY DESIGN
In a pharmaceutical QbD approach to product develop-
ment, an applicant identiﬁes characteristics that are critical to
quality from the patient’s perspective, translates them into the
drug product critical quality attributes (CQAs), and estab-
lishes the relationship between formulation/manufacturing
variables and CQAs to consistently deliver a drug product
with such CQAs to the patient. QbD consists of the following
elements:
1. A quality target product proﬁle (QTPP) that identiﬁes
the critical quality attributes (CQAs) of the drug
product
2. Product design and understanding including the
identiﬁcation of critical material attributes (CMAs)
3. Process design and understanding including the iden-
tiﬁcation of critical process parameters (CPPs) and a
thorough understanding of scale-up principles, linking
CMAs and CPPs to CQAs
4. A control strategy that includes speciﬁcations for the
drug substance(s), excipient(s), and drug product as
well as controls for each step of the manufacturing
process
5. Process capability and continual improvement
Quality Target Product Profile that Identifies the Critical
Quality Attributes of the Drug Product
QTPP is a prospective summary of the quality charac-
teristics of a drug product that ideally will be achieved to
ensure the desired quality, taking into account safety and
efﬁcacy of the drug product. QTPP forms the basis of design
for the development of the product. Considerations for
inclusion in the QTPP could include the following (3):
& Intended use in a clinical setting, route of adminis-
tration, dosage form, and delivery system(s)
& Dosage strength(s)
& Container closure system
& Therapeutic moiety release or delivery and attributes
affecting pharmacokinetic characteristics (e.g., disso-
lution and aerodynamic performance) appropriate to
the drug product dosage form being developed
& Drug product quality criteria (e.g., sterility, purity,
stability, and drug release) appropriate for the
intended marketed product
Identiﬁcation of the CQAs of the drug product is the
next step in drug product development. A CQA is a
physical, chemical, biological, or microbiological property
or characteristic of an output material including ﬁnished
drug product that should be within an appropriate limit,
range, or distribution to ensure the desired product
quality (3). The quality attributes of a drug product may
include identity, assay, content uniformity, degradation
products, residual solvents, drug release or dissolution,
moisture content, microbial limits, and physical attributes
such as color, shape, size, odor, score conﬁguration, and
friability. These attributes can be critical or not critical.
Criticality of an attribute is primarily based upon the
severity of harm to the patient should the product fall
outside the acceptable range for that attribute. Probability
of occurrence, detectability, or controllability does not
impact criticality of an attribute.
It seems obvious that a new product should be ade-
quately deﬁned before any development work commences.
However, over the years, the value of predeﬁning the target
characteristics of the drug product is often underestimated.
Consequently, the lack of a well-deﬁned QTPP has resulted in
wasted time and valuable resources. A recent paper by Raw
772 Yu et al.
et al. (12) illustrates the signiﬁcance of deﬁning the correct
QTPP before conducting any development. Also, QbD exam-
ples exemplify the identiﬁcation and use of QTPPs (20–22).
Product Design and Understanding
Over the years, QbD’s focus has been on the process
design, understanding, and control, as discussed in the ICH
Q8 (R2) guidance (3). It should be emphasized that product
design, understanding, and control are equally important.
Product design determines whether the product is able to
meet patients’ needs, which is conﬁrmed with clinical studies.
Product design also determines whether the product is able to
maintain its performance through its shelf life, which is
conﬁrmed with stability studies. This type of product under-
standing could have prevented some historical stability
failures.
The key objective of product design and understanding is
to develop a robust product that can deliver the desired
QTPP over the product shelf life. Product design is open-
ended and may allow for many design pathways. Key
elements of product design and understanding include the
following:
& Physical, chemical, and biological characterization of
the drug substance(s)
& Identiﬁcation and selection of excipient type and
grade, and knowledge of intrinsic excipient variability
& Interactions of drug and excipients
& Optimization of formulation and identiﬁcation of
CMAs of both excipients and drug substance
To design and develop a robust drug product that has the
intended CQAs, a product development scientist must give
serious consideration to the physical, chemical, and biological
properties of the drug substance. Physical properties include
physical description (particle size distribution and particle
morphology), polymorphism and form transformation, aqueous
solubility as a function of pH, intrinsic dissolution rate,
hygroscopicity, and melting point(s). Pharmaceutical solid
polymorphism, for example, has received much attention
recently since it can impact solubility, dissolution, stability, and
manufacturability. Chemical properties include pKa, chemical
stability in solid state and in solution, as well as photolytic and
oxidative stability. Biological properties include partition coef-
ﬁcient, membrane permeability, and bioavailability.
Pharmaceutical excipients are components of a drug
product other than the active pharmaceutical ingredient.
Excipients can (1) aid in the processing of the dosage
form during its manufacture; (2) protect, support, or
enhance stability, bioavailability, or patient acceptability;
(3) assist in product identiﬁcation; or (4) enhance any
other attribute of the overall safety, effectiveness, or
delivery of the drug during storage or use (23). They
are classiﬁed by the functions they perform in a pharma-
ceutical dosage form. Among 42 functional excipient
categories listed in USP/NF (24), commonly used excipi-
ents include binders, disintegrants, ﬁllers (diluents), lubri-
cants, glidants (ﬂow enhancers), compression aids, colors,
sweeteners, preservatives, suspending/dispersing agents,
pH modiﬁers/buffers, tonicity agents, ﬁlm formers/coatings,
ﬂavors, and printing inks. The FDA’s inactive ingredients
database (25) lists the safety limits of excipients based on
prior use in FDA-approved drug products.
It is well recognized that excipients can be a major
source of variability. Despite the fact that excipients can alter
the stability, manufacturability, and bioavailability of drug
products, the general principles of excipient selection are not
well-deﬁned, and excipients are often selected ad hoc without
systematic drug-excipient compatibility testing. To avoid
costly material wastage and time delays, ICH Q8 (R2)
recommends drug-excipient compatibility studies to facilitate
the early prediction of compatibility (3). Systematic drug-
excipient compatibility studies offer several advantages as
follows: minimizing unexpected stability failures which usual-
ly lead to increased development time and cost, maximizing
the stability of a formulation and hence the shelf life of the
drug product, and enhancing the understanding of drug-
excipient interactions that can help with root cause analysis
should stability problems occur.
Formulation optimization studies are essential in developing a
robust formulation that is not on the edge of failure. Without
optimization studies, a formulation is more likely to be high risk
because it is unknownwhether any changes in the formulation itself
or in the raw material properties would signiﬁcantly impact the
quality and performance of the drug product, as shown in recent
examples (26,27). Formulation optimization studies provide impor-
tant information on the following:
& Robustness of the formulation including establishing
functional relationships between CQAs and CMAs
& Identiﬁcation of CMAs of drug substance, excipients,
and in-process materials
& Development of control strategies for drug substance
and excipients
In a QbD approach, it is not the number of optimization
studies conducted but rather the relevance of the studies and
the utility of the knowledge gained for designing a quality
drug product that is paramount. As such, the QbD does not
equal design of experiments (DoE), but the latter could be an
important component of QbD.
Drug substance, excipients, and in-process materials may
have many CMAs. A CMA is a physical, chemical, biological,
or microbiological property or characteristic of an input
material that should be within an appropriate limit, range,
or distribution to ensure the desired quality of that drug
substance, excipient, or in-process material. For the purpose
of this paper, CMAs are considered different from CQAs in
that CQAs are for output materials including product
intermediates and ﬁnished drug product while CMAs are for
input materials including drug substance and excipients. The
CQA of an intermediate may become a CMA of that same
intermediate for a downstream manufacturing step.
Since there are many attributes of the drug substance
and excipients that could potentially impact the CQAs of the
intermediates and ﬁnished drug product, it is unrealistic that a
formulation scientist investigate all the identiﬁed material
attributes during the formulation optimization studies. There-
fore, a risk assessment would be valuable in prioritizing which
material attributes warrant further study. The assessment
should leverage common scientiﬁc knowledge and the
formulator’s expertise. A material attribute is critical when a
realistic change in that material attribute can have a
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Table I. Typical Input Material Attributes, Process Parameters, and Quality Attributes of Pharmaceutical Unit Operations
Pharmaceutical unit operation
Input material attributes Process parameters Quality attributes
Blending/mixing
• Particle size
• Particle size distribution
• Fines/oversize
• Particle shape
• Bulk/tapped/true density
• Cohesive/adhesive properties
• Electrostatic properties
• Moisture content
• Type and geometry of mixer
• Mixer load level
• Order of addition
• Number of revolutions (time and speed)
• Agitating bar (on/off pattern)
• Discharge method
• Holding time
• Environment temperature and RH
• Blend uniformity
• Potency
• Particle size
• Particle size distribution
• Bulk/tapped/true density
• Moisture content
• Flow properties
• Cohesive/adhesive properties
• Powder segregation
• Electrostatic properties
Size reduction/comminution
• Particle/granule size
• Particle/granule size
distribution
• Fines
• Particle/granule shape
• Bulk/tapped/true density
• Adhesive properties
• Electrostatic properties
• Hardness/plasticity
• Viscoelasticity
• Brittleness
• Elasticity
• Solid form/polymorph
• Moisture content
• Granule porosity/density
Ribbon milling
• Ribbon dimensions
• Ribbon density
• Ribbon porosity/solid fraction
Impact/cutting/screening mills
• Mill type
• Speed
• Blade conﬁguration, type, orientation
• Screen size and type
• Feeding rate
Fluid energy mill
• Number of grinding nozzles
• Feed rate
• Nozzle pressure
• Classiﬁer
Granule/ribbon milling
• Mill type
• Speed
• Blade conﬁguration, type, orientation
• Screen size and type
• Feeding rate
• Particle/granule size
• Particle/granule size distribution
• Particle/granule shape
• Particle/granule shape factor
(e.g., aspect ratio)
• Particle/granule density/Porosity
• Bulk/tapped/true density
• Flow properties
• API polymorphic form
• API crystalline morphology
• Cohesive/adhesive properties
• Electrostatic properties
• Hardness/Plasticity
• Viscoelasticity
• Brittleness
• Elasticity
Wet granulation
• Particle size distribution
• Fines/Oversize
• Particle shape
• Bulk/tapped/true density
• Cohesive/adhesive properties
• Electrostatic properties
• Hardness/plasticity
• Viscoelasticity
• Brittleness
• Elasticity
• Solid form/polymorph
• Moisture content
High/low shear granulation
• Type of granulator (High/low shear, top/bottom drive)
• Fill level
• Pregranulation mix time
• Granulating liquid or solvent quantity
• Impeller speed, tip speed, conﬁguration, location, power
consumption/torque
• Chopper speed, conﬁguration, location, power consumption
• Spray nozzle type and location
• Method of binder excipient addition (dry/wet)
• Method of granulating liquid addition (spray or pump)
• granulating liquid temperature
• granulating liquid addition rate and time
• Wet massing time (post-granulation mix time)
• Bowl temperature(jacket temperature)
• Product temperature
• Post mixing time
• Pump Type: Peristaltic, Gear type
• Granulating liquid vessel (e.g., pressurized, heated)
Fluid bed granulation
• Type of ﬂuid bed
• Inlet air distribution plate
• Spray nozzle (tip size, type/quantity/ pattern/conﬁguration/position)
• Filter type and oriﬁce size
• Endpoint measurement
(e.g., power consumption, torque,
etc.)
• Blend uniformity
• Potency
• Flow
• Moisture content
• Particle size and distribution
• Granule size and distribution
• Granule strength and uniformity
• Bulk/tapped/true density
• API polymorphic form
• Cohesive/adhesive properties
• Electrostatic properties
• Granule brittleness
• Granule elasticity
• Solid form/polymorph
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Table I. (continued)
Pharmaceutical unit operation
Input material attributes Process parameters Quality attributes
• Fill level
• Bottom screen size and type
• Preheating temperature/time
• Method of binder excipient addition (dry/wet)
• Granulating liquid temperature
• Granulating liquid quantity
• Granulating liquid concentration/viscosity
• Granulating liquid holding time
• Granulating liquid delivery method
• Granulating liquid spray rate
• Inlet air, volume, temperature, dew point
• Atomization air pressure
• Product and ﬁlter pressure differentials
• Product temperature
• Exhaust air temperature, ﬂow
• Filter shaking interval and duration
Drying
• Particle size, distribution
• Fines/oversize
• Particle shape
• Cohesive/adhesive properties
• Electrostatic properties
• Hardness/plasticity
• Viscoelasticity
• Brittleness
• Elasticity
• Solid form/polymorph
• Moisture content
Fluidized bed
• Inlet air volume, temperature, dew point
• Product temperature
• Exhaust air temperature, ﬂow
• Filter type and oriﬁce size
• Shaking interval and duration
• Total drying time
Tray
• Type of tray dryer
• Bed thickness/tray depth (depth of product per tray)
• Type of drying tray liner (e.g., paper, plastic,
synthetic ﬁber, etc.)
• Quantity carts and trays per chamber
• Quantity of product per tray
• Drying time and temperature
• Air ﬂow
• Inlet dew point
Vacuum/microwave
• Jacket temperature
• Condenser temperature
• Impeller speed
• Bleed air volume
• Vacuum pressure
• Microwave power
• Electric ﬁeld
• Energy supplied
• Product temperature
• Bowl and lid temperature
• Total drying time
• Granule size and distribution
• Granule strength, uniformity
• Flow
• Bulk/tapped/true density
• Moisture content
• Residual solvents
• API polymorphic form or transition
• Purity proﬁle
• Moisture proﬁ le (e.g. product
temperature vs. LOD)
• Potency
• Cohesive/adhesive properties
• Electrostatic properties
Roller compaction/chilsonation
• Particle size, distribution
• Fines/oversize
• Particle shape
• Cohesive/adhesiveproperties
• Electrostatic properties
• Hardness/plasticity
• Bulk/tapped/true density
• Viscoelasticity
• Brittleness
• Elasticity
• Type of roller compactor
• Auger (feed screw) type/design (horizontal,
vertical or angular)
• Deaeration (e.g., vacuum)
• Auger (feed screw) speed
• Roll shape (cylindrical or interlocking).
• Roll surface design (smooth, knurled, serrated,
or pocketed)
• Roll gap width (e.g., ﬂexible or ﬁxed)
• Roll speed
• Roll pressure
• Ribbon appearance (edge attrition,
splitting, lamination, color, etc.)
• Ribbon thickness
• Ribbon density (e.g. , envelop
density)
• Ribbon porosity/solid fraction
• Ribbon tensile strength/breaking
force
• Throughput rate
• APIpolymorphic formand transition
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Table I. (continued)
Pharmaceutical unit operation
Input material attributes Process parameters Quality attributes
• Solid form/polymorph • Roller temperature
• Fines recycled (yes or no, # of cycles)
Extrusion–Spheronization
• Particle size, distribution
• Fines/oversize
• Particle shape
• Cohesive/adhesiveproperties
• Electrostatic properties
• Hardness/plasticity
• Bulk/tapped/truedensity
• Viscoelasticity
• Brittleness
• Elasticity
• Solid form/polymorph
• Type of extruder (screw or basket)
• Screw length, pitch, and diameter
• Screw channel depth
• Screw blade conﬁguration
• Number of screws (single/dual)
• Die or screen conﬁguration (e.g., radial or axial)
• Die length/diameter ratio
• Roll diameter (mm)
• Screen opening diameter (mm)
• Screw speed (rpm)
• Feeding rate (g/min)
• Type and scale of spheronizer
• Spheronizer load level
• Plate geometry and speed
• Plate groove design (spacing and pattern)
• Air ﬂow
• Residence time
• Extrudate
• Density
• Length/thickness/diameter
• Moisture content
• API polymorphic form and transition
• Content uniformity
• Throughput
• Pellets after spheronization
• Pellets size and distribution
• Pellets shape factor (e.g. aspect
ratio)
• Bulk/Tapped density
• Flow properties
• Brittleness
• Elasticity
• Mechanical strength
• Friability
Hot melt extrusion
• Particle size, distribution
• Fines/oversize
• Particle shape
• Melting point
• Density
• Solid form/polymorph
• Moisture content
• Screw design (twin/single)
• Screw speed
• Screw opening diameter (mm)
• Solid and liquid feed rates
• Feeder type/design
• Feed rate
• No. of zones
• Zone temperatures
• Chilling rate
• Extrudate density
• Length/thickness/diameter
• Polymorphic form and transition
• Content uniformity
• Throughput
Tabletting
• Particle/granule size
and distribution
• Fines/oversize
• Particle/granule shape
• Cohesive/adhesive
properties
• Electrostatic properties
• Hardness/plasticity
• Bulk/tapped/true density
• Viscoelasticity
• Brittleness
• Elasticity
• Solid form/polymorph
• Moisture
• Type of press (model, geometry, number of stations)
• Hopper design, height, angle, vibration
• Feeder mechanism (gravity/forced feed, shape of wheels,
direction of rotation, number of bars)
• Feed frame type and speed
• Feeder ﬁll depth
• Tooling design (e.g., dimension, score conﬁguration,
quality of the metal)
• Maximum punch load
• Press speed/dwell time
• Precompression force
• Main compression force
• Punch penetration depth
• Ejection force
• Dwell Time
• Tablet appearance
• Tablet weight
• Weight uniformity
• Content uniformity
• Hardness/tablet breaking force/
tensile strength
• Thickness/dimensions
• Tablet porosity/density/solid fraction
• Friability
• Tablet defects
• Moisture content
• Disintegration
• Dissolution
Encapsulation
• Particle/granule size and
distribution
• Fines/oversize
• Particle/granule shape
• Cohesive/adhesiveproperties
• Electrostatic properties
• Hardness/plasticity
• Bulk/tapped/true density
• Viscoelasticity
• Brittleness
• Machine type
• Machine ﬁll speed
• Tamping Force
• No. of tamps
• Auger screw design/speed
• Powder bed height
• Capsule appearance
• Weight
• Weight uniformity
• Content uniformity
• Moisture content
• Slug tensile strength
• Disintegration
• Dissolution
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• Elasticity
• Solid form/polymorph
• Moisture
Pan coating
• Tablet dimensions
• Tablet defects
• Hardness/plasticity
• Density
• Porosity
• Moisture content
• Type of pan coater (conventional or side-vented)
• Pan (fully perforated or partial perforated)
• Bafﬂe (design, number, location)
• Pan load level
• Pan rotation speed
• Spray nozzle (type, quantity, pattern, conﬁguration,
spray pattern)
• Nozzle to bed distance
• Distance between nozzles
• Nozzle orientation
• Total preheating time
• Inlet air ﬂow rate, volume, temperature, dew point
• Product temperature
• Individual nozzle spray rate
• Total spray rate
• Atomization air pressure
• Pattern air pressure
• Exhaust air temperature, air ﬂow
• Total coating, curing time and drying time
• Coating efﬁciency
• Core tablet weight before and after
preheating
• Moisture (gain/loss) during
preheating
• Environmental equivalency factor
• Coated drug product (e.g., tablet or
capsule) appearance
• % weight gain
• Film thickness
• Coating (polymer and /or color)
uniformity
• Hardness/breaking force/Tensile
strength
• Friability
• Moisture (gain/loss) during overall
process
• Residual solvent(s)
• Disintegration
• Dissolution
• Tablet defects
• Visual attributes
Fluid bed coating
• Tablet dimensions
• Tablet defects
• Hardness/plasticity
• Density/porosity
moisture content
• Type of ﬂuid bed coater
• Fluid bed load level
• Partition column diameter
• Partition column height
• Number of partition columns
• Air distribution plate type and size
• Filter type and oriﬁce size
• Filter differential pressure
• Filter shaking interval and duration
• Spray nozzle (type, quantity, pattern, conﬁguration)
• Nozzle port size
• Total preheating time
• Spray rate per nozzle
• Total spray rate
• Atomization air pressure
• Inlet air ﬂow rate, volume, temperature, dew point
• Product temperature
• Exhaust air temperature, air ﬂow
• Total coating, curing and drying time
• Coating efﬁciency
• Core tablet weight before and after
preheating
• Moisture (gain/loss) during
preheating
• Environmental equivalency factor
• Coated drug product (e.g., tablet or
capsule) appearance
• % weight gain
• Film thickness
• Coating (polymer and /or color)
uniformity
• Hardness/breaking force/tensile
strength
• Friability
• Moisture (gain/loss) during overall
process
• Residual solvent(s)
• Disintegration
• Dissolution
• Tablet defects
• Visual attributes
Laser drilling
• Size/dimensions
• Polymer type
membrane thickness
• Conveyor type
• Conveyor speed
• Laser power
• Number of pulses
• Type(s) of lens(es)
• One or two sided
• Number of holes
• Opening diameter (internal and
external)
• Depth
• Shape of the opening
Table I. (continued)
Pharmaceutical unit operation
Input material attributes Process parameters Quality attributes
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signiﬁcant impact on the quality of the output material.
Product understanding includes the ability to link input
CMAs to output CQAs. The steps taken to gain product
understanding may include the following:
1. Identify all possible known input material attributes
that could impact the performance of the product
2. Use risk assessment and scientiﬁc knowledge to
identify potentially high risk attributes
3. Establish levels or ranges of these potentially high-risk
material attributes
4. Design and conduct experiments, using DoE when
appropriate
5. Analyze the experimental data and, when possible, apply
ﬁrst principle models to determine if an attribute is critical
6. Develop a control strategy. For critical material
attributes, deﬁne acceptable ranges. For noncritical
material attributes, the acceptable range is the range
investigated. When more than one excipient is in-
volved, these deﬁned acceptable ranges may be
termed formulation design space
Process Design and Understanding
A pharmaceutical manufacturing process usually consists
of a series of unit operations to produce the desired quality
product. Unit operations may be executed in batch mode or in a
continuousmanufacturing process. A unit operation is a discrete
activity that involves physical or chemical changes, such as
mixing, milling, granulation, drying, compression, and coating.
A process is generally considered well-understood when (1) all
critical sources of variability are identiﬁed and explained, (2)
variability is managed by the process, and (3) product quality
attributes can be accurately and reliably predicted (28).
Process parameters are referred to as the input operating
parameters (e.g., speed and ﬂow rate) or process state variables
(e.g., temperature and pressure) of a process step or unit operation.
A process parameter is critical when its variability has an impact on
a critical quality attribute and therefore should be monitored or
controlled to ensure the process produces the desired quality.
Under this deﬁnition, the state of a process depends on its CPPs
and the CMAs of the input materials. Table I lists the typical
manufacturing unit operations, material attributes, process param-
eters, and quality attributes for solid oral dosage forms.
Process robustness is the ability of a process to deliver
acceptable drug product quality and performance while tolerating
variability in the process and material inputs (29). The effects of
variations in process parameters and material attributes are
investigated in process robustness studies. The analysis of these
experiments identiﬁes CPPs that could affect drug product quality
and establishes limits for these CPPs (and CMAs) within which
the quality of drug product is assured. The relationship between
input CMAs and CPPs and output CQAs is shown in Fig. 1.
Steps to establish process understanding are very similar
to those of product understanding and include the following:
1. Identify all possible known process parameters that
could impact the performance of the process
2. Use risk assessment and scientiﬁc knowledge to
identify potentially high-risk parameters
3. Establish levels or ranges of these potentially high-risk
parameters
4. Design and conduct experiments, using DoE when
appropriate
5. Analyze the experimental data and, when possible,
determine scalability and apply ﬁrst principle models
to determine if a process parameter is critical. Link
CMAs and CPPs to CQAs when possible.
6. Develop a control strategy. For critical parameters,
deﬁne acceptable ranges. For noncritical parameters,
the acceptable range is the range investigated. When
more than one process parameter or material attribute
is involved, these deﬁned acceptable ranges may be
termed process design space
While developing a strategy for investigating both
product design and understanding and process design and
understanding, studies can be designed in such a way that
both the objectives of product and process understanding are
achieved simultaneously. In addition, an interactive (or
interdependent) relationship among material attributes, pro-
cess parameters, and product attributes can be more easily
developed when such analyses are performed in carefully
planned and designed experimental studies.
ICH Q8 (R2) deﬁnes design space as the multidimen-
sional combination and interaction of input variables (e.g.,
material attributes) and process parameters that have been
demonstrated to provide assurance of quality (3). Parameter
movements that occur within the design space are not
subjected to regulatory notiﬁcation. However, movement
out of the design space is considered to be a change and
would normally initiate a regulatory postapproval change
process. Design space is proposed by the applicant and is
subject to regulatory assessment and approval. Thus, design
space is the direct outcome of analysis of the DoE data or
validated models such as ﬁrst-principle models.
Design space may be scale and equipment dependent.
Therefore, the design space determined at laboratory scale
may need to be justiﬁed for use at commercial scale.
Approaches for justiﬁcation may include geometric consider-
ations, kinematic considerations, heat and mass transfer, or
dimensionless numbers as well as continual veriﬁcation
during commercial manufacturing. Justiﬁcation is needed
because the mechanistic understanding of pharmaceutical
unit operations may be limited and scale-up is largely based
on general rule of thumb and trial-and-error approaches;
however, when mechanistic understanding or reliable
Pharmaceutical 
Unit 
OperationInput 
Materials
Output 
Materials or
Product
CPPs
CMAs CQAs
CQAs = f (CPP1, CPP2 , CPP3 …CMA1, CMA2, CMA3…)
Fig. 1. Link input critical material attributes (CMAs) and critical
process parameters (CPPs) to output critical quality attributes
(CQAs) for a unit operation
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empirical models (i.e., extensive process understanding)
exists, then the design space can be translated across scale.
Pharmaceutical products are frequently manufactured by
a combination of unit operations. For example, tablets
prepared by direct compression may simply involve blending
and compression. However, when tablets are prepared by wet
granulation, unit operations may involve blending, granula-
tion, wet milling, drying, dry milling, blending for lubrication,
compression, coating, and packaging. In such cases, the
output of the ﬁrst unit operation becomes an input of
subsequent unit operations. Process understanding could be
conducted on each unit operation or a combination of unit
operations to determine CMAs, CPPs, and CQAs. Figure 2
shows an example how the CMAs and CPPs were deter-
mined, using an example of an immediate release dosage
form (20).
Control Strategy
The knowledge gained through appropriately designed
development studies culminates in the establishment of a
control strategy. As shown in Fig. 3, control strategy could
include three levels of controls as follows:
Level 1 utilizes automatic engineering control to
monitor the CQAs of the output materials in real time. This
level of control is the most adaptive. Input material attributes
are monitored and process parameters are automatically
adjusted to assure that CQAs consistently conform to the
established acceptance criteria. Level 1 control can enable
real-time release testing and provides an increased level of
quality assurance compared to traditional end-product test-
ing. It should be noted that adoption of process analytical
technology (PAT) is not the only way to implement real-time
release testing (e.g., the use of predictive models as a
surrogate for traditional release test, where the model may
be deﬁned in terms of traditional in-process measurements).
Level 2 consists of pharmaceutical control with reduced
end-product testing and ﬂexible material attributes and process
parameters within the established design space. QbD fosters
product and process understanding and facilitates identiﬁcation
of the sources of variability that impact product quality.
Understanding the impact that variability has on in-process
materials, downstream processing, and drug product quality
provides an opportunity to shift controls upstream and to reduce
the reliance on end-product testing (3).
Level 3 is the level of control traditionally used in the
pharmaceutical industry. This control strategy relies on extensive
end-product testing and tightly constrained material attributes
and process parameters. Due to limited characterization of the
sources of variability and inadequate understanding of the
impact that CMAs and CPPs have on the drug product CQAs,
any signiﬁcant change in these requires regulatory oversight.
Signiﬁcant industry and regulatory resources are spent debating
issues related to acceptable variability, the need for additional
controls, and the establishment of acceptance criteria.
In reality, a hybrid approach combining levels 1 and 2
can be used. ICH Q8 (R2) (3) deﬁnes a control strategy as a
planned set of controls, derived from current product and
process understanding that ensures process performance and
product quality. The controls can include parameters and
attributes related to drug substance and drug product
materials and components, facility and equipment operating
conditions, in-process controls, ﬁnished product speciﬁca-
tions, and the associated methods and frequency of monitor-
ing and control. A control strategy can include, but is not
limited to, the following (3):
Critical Material Attributes*
Material Attributes
Critical Process Parameters*
Process Parameters
Risk Assessment
Prior Knowledge
First Principle
DoEs
Physicochemical
Assay
Content Uniformity
Dissolution
Safety
Stability
Degradation Products
Efficacy
Bioavailability
Drug Product
Critical Quality Attributes
(Part of QTPP)
DoEs  & Scale-up
-With interactions and 
quadratic responses
-Univariate OK if  
proven that there are 
no interactions
DoEs & Scale-up
-With interactions 
and quadratic 
responses
-Univariate OK if  
proven that there are 
no interactions
Acetriptan [solid state form, solubility, morphology, particle size distribution (PSD), bulk, 
density, flowability, cohesiveness, moisture content, hygroscopicity, chemical stability, 
process impurities, residual solvents, etc…]
Lactose [type, grade, source, amount, polymorphism, PSD, morphology, aspect ratio, bulk, 
density, moisture content, flowability, compressibility, lot-to-lot variability, etc…]
Microcrystalline Cellulose (MCC) [type, grade, source, amount, PSD, bulk, density, 
morphology, flowability, moisture, content, compressibility, lot-to-lot variability, etc…]
Croscarmellose [type, grade, source, amount, degree of substitution, PSD, moisture 
content, lot-to-lot variability, etc…]
Talc [type, grade, amount, PSD, density, specific surface area, moisture content, lot-to-lot 
variability, etc…]
Mg St [type, grade, source, amount, PSD, specific surface area, moisture content, lot-to-lot 
variability, etc…]
Pre-roller compaction blending and lubrication [blender type, order of addition, fill 
level, rotation speed, time, number of revolutions, intensifier bar (on/off), 
environment (temp and RH), etc…]
Roller compaction [compactor type, feed screw speed, deaeration, roller surface 
design, roller pressure, roller speed, roller gap, environment (temp and RH), etc…]
Milling [Mill type, blade configuration, speed, screen type, mesh size, # of recycles, 
environment (temp and RH), etc…]
Final blending and Lubrication [blender type, order of addition, fill level, rotation 
speed, time, number of revolutions, intensifier bar (on/off), environment (temp and 
RH), etc…]
Compression [Press type, number of stations, tooling design, feed frame paddle speed, 
feeder fill depth, pre-compression force, main compression force, press speed 
(dwell time), hopper design, hopper fill level, drop height of finished tablets, run 
time, environment (temp and RH), etc…]
*Conclusion is drawn based upon the ranges studied and the control strategy for other variables (fixed or controlled within the ranges studied)
Acetriptan: PSD, polymorphic form
Lactose and MCC: amount and ratio
Croscarmellose: amount
Talc: amount
Mg St: amount
(Note: Excipients type, grade, and source are fixed and its quality is 
controlled per compendial/in-house specifications.)
Pre-roller compaction blending and lubrication: 
number of  revolutions
Roller compaction: roller pressure and roller gap
Milling: mill screen orifice size
Final blending and Lubrication: none within the ranges studied
Compression: main compression force
Fig. 2. Product and process understanding: an example for immediate release dosage forms
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& Control of input material attributes (e.g., drug substance,
excipient, in process material, and primary packaging
material) based on an understanding of their impact on
processability or product quality
& Product speciﬁcation(s)
& Controls for unit operations that have an impact on
downstream processing or product quality (e.g., the impact
of drying on degradation and particle size distribution of
the granulate on dissolution)
& In-process or real-time release testing in lieu of end-product
testing (e.g., measurement and control of CQAs during
processing)
& A monitoring program (e.g., full product testing at regular
intervals) for verifying multivariate prediction models
Process Capability and Continual Improvement
Process capability measures the inherent variability of a
stable process that is in a state of statistical control in
relation to the established acceptance criteria. Table II
shows the deﬁnition, calculation formula, and description of
process capability indices (30) that are useful for monitoring
the performance of pharmaceutical manufacturing process-
es. Calculations based on the inherent variability due to
common cause of a stable process (i.e., in a state of
statistical control) result in process capability (Cp and Cpk)
indices. When the process has not been demonstrated to be
in a state of statistical control, the calculation needs to be
based on sample standard deviation of all individual
(observed) samples taken over a longer period of time; the
result is a process performance index (Pp and Ppk). A state
of statistical control is achieved when the process exhibits
no detectable patterns or trends, such that the variation
seen in the data is believed to be random and inherent to
the process (31).
When a process is not in a state of statistical control, it is
because the process is subject to special cause (source of
intermittent variation in a process). Special causes can give rise
to short-term variability of the process or can cause long-term
shifts or drifts of the processmean. Special causes can also create
transient shifts or spikes in the processmean. On the other hand,
common cause is a source of inherent variation that is random,
always present, and affects every outcome of the process. In a
QbD development process, the product and process under-
standing gained during pharmaceutical development should
result in early identiﬁcation and mitigation of potential sources
of common cause variation via the control strategy. The
manufacturing process will move toward a state of statistical
control, and, once there, the manufacturer will continue to
improve process capability by reducing or removing some of the
random causes present and/or adjusting the process mean
towards the preferred target value to the beneﬁt of the patient.
In a non-QbD approach, common cause variation is more likely
to be discovered during commercial production and may
interrupt commercial production and cause drug shortage when
it will require a root cause analysis.
Process capability can be used to measure process
improvement through continuous improvement efforts that
focus on removing sources of inherent variability from the
process operation conditions and raw material quality.
Ongoing monitoring of process data for Cpk and other
measures of statistical process control will also identify when
special variations occur that need to be identiﬁed and
corrective and preventive actions implemented.
Continuous improvement is a set of activities that the
applicant carries out in order to enhance its ability to meet
requirements. Continual improvements typically have ﬁve
phases as follows (32):
& Deﬁne the problem and the project goals, speciﬁcally
& Measure key aspects of the current process and
collect relevant data
& Analyze the data to investigate and verify cause-and-
effect relationships. Determine what the relationships
are, and attempt to ensure that all factors have been
considered. Seek out root cause of the defect if any.
Table II. Process Capability Indices and Their Measures
Index Description
Cp ¼ USL−LSLð Þ6bσ Estimates process capability when the data mean is centered between upper and lower speciﬁcation limits.
Cpkl ¼ Mean−LSLð Þ3bσ Estimates process capability when the data mean is not centered between upper and lower speciﬁcation limits or when
speciﬁcations consist of a lower limit only.
Cpku ¼ USL−Meanð Þ3bσ Estimates process capability when the data mean is not centered between upper and lower speciﬁcation limits or when
speciﬁcations consist of an upper limit only.
USL upper speciﬁcation limit, LSL lower speciﬁcation limit, bσ (sigma hat) inherent variability due to common cause of a stable process
Fig. 3. Control strategy implementation options
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& Improve or optimize the current process based upon
data analysis using techniques such as design of
experiments to create a new, future state process.
Set up pilot runs to establish process capability.
& Control the future state process to ensure that any
deviations from target are corrected before they
result in defects. Implement control systems such as
statistical process control, production boards, visual
workplaces, and continuously monitor the process.
In addition, continuous improvement can apply to legacy
products. Legacy products usually have a large amount of
historical manufacturing data. Using multivariate analysis to
examine the data could uncover major disturbances in the form
of variability in raw materials and process parameters. Contin-
uous improvement could be achieved by reducing and control-
ling this variability. Newer processes associated with a design
space facilitate continuous process improvement since appli-
cants will have regulatory ﬂexibility to move within the design
space (ICH Q8).
PHARMACEUTICAL QUALITY BY DESIGN TOOLS
Prior Knowledge
Although not ofﬁcially deﬁned, the term “prior knowl-
edge” has been extensively used in workshops, seminars,
and presentations. In regulatory submissions, applicants
often attempt to use prior knowledge as a “legitimate”
reason for substitution of scientiﬁc justiﬁcations or
conducting necessary scientiﬁc studies.
Knowledge may be deﬁned as a familiarity with someone
or something, which can include information, facts, descrip-
tions, and/or skills acquired through experience or education.
The word “prior” in the term “prior knowledge” not only
means “previous,” but also associates with ownership and
conﬁdentiality, not available to the public. Thus, for the
purpose of this paper, prior knowledge can only be obtained
through experience, not education. Knowledge gained
through education or public literature may be termed public
knowledge. Prior knowledge in the QbD framework general-
ly refers to knowledge that stems from previous experience
that is not in publically available literature. Prior knowledge
may be the proprietary information, understanding, or skill
that applicants acquire through previous studies.
Risk Assessment
ICH Q9 quality risk management indicates that “the
manufacturing and use of a drug product, including its
components, necessarily entail some degree of risk.… The
evaluation of the risk to quality should be based on scientiﬁc
knowledge and ultimately link to the protection of the patient
and the level of effort, formality, and documentation of the
quality risk management process should be commensurate with
the level of risk (4).” The purpose of ICH Q9 is to offer a
systematic approach to quality risk management and does not
speciﬁcally address risk assessment in product development.
However, the risk assessment tools identiﬁed in ICH Q9 are
applicable to risk assessment in product development also.
The purpose of risk assessment prior to development
studies is to identify potentially high-risk formulation and
process variables that could impact the quality of the drug
product. It helps to prioritize which studies need to be conducted
and is often driven by knowledge gaps or uncertainty. Study
results determine which variables are critical and which are not,
which facilitates the establishment of a control strategy. The
outcome of the risk assessment is to identify the variables to be
experimentally investigated. ICH Q9 (4) provides a
nonexhaustive list of common risk assessment tools as follows:
& Basic risk management facilitation methods (ﬂow-
charts, check sheets, etc.)
& Fault tree analysis
& Risk ranking and ﬁltering
& Preliminary hazard analysis
& Hazard analysis and critical control points
& Failure mode effects analysis
& Failure mode, effects, and criticality analysis
& Hazard operability analysis
& Supporting statistical tools
It might be appropriate to adapt these tools for use in speciﬁc
areas pertaining to drug substance and drug product quality.
Mechanistic Model, Design of Experiments, and Data
Analysis
Product and process understanding is a key element of
QbD. To best achieve these objectives, in addition to mechanis-
tic models, DoE is an excellent tool that allows pharmaceutical
scientists to systematically manipulate factors according to a
prespeciﬁed design. TheDoEalso reveals relationships between
input factors and output responses. A series of structured tests
are designed in which planned changes are made to the input
variables of a process or system. The effects of these changes on
a predeﬁned output are then assessed. The strength ofDoEover
the traditional univariate approach to development studies is the
ability to properly uncover how factors jointly affect the output
responses. DoE also allows us to quantify the interaction terms
of the variables. DoE is important as a formal way of
maximizing information gained while minimizing the resources
required. DoE studies may be integrated with mechanism-based
studies to maximize product and process understanding.
When DoE is applied to formulation or process devel-
opment, input variables include the material attributes (e.g.,
particle size) of raw material or excipients and process
parameters (e.g., press speed or spray rate), while outputs
are the critical quality attributes of the in-process materials or
ﬁnal drug product (e.g., blend uniformity, particle size or
particle size distribution of the granules, tablet assay, content
uniformity, or drug release). DoE can help identify optimal
conditions, CMAs, CPPs, and, ultimately, the design space.
FDA scientists have shown the use of DoE in product and
process design in recent publications (33–39).
Process Analytical Technology
The application of PAT may be part of the control
strategy (28). ICH Q8 (R2) identiﬁes the use of PAT to
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ensure that the process remains within an established design
space (3). PAT can provide continuous monitoring of CPPs,
CMAs, or CQAs to make go/no go decisions and to
demonstrate that the process is maintained in the design
space. In-process testing, CMAs, or CQAs can also be
measured online or inline with PAT. Both of these applica-
tions of PAT are more effective at detecting failures than end-
product testing alone. In a more robust process, PAT can
enable active control of CMAs and/or CPPs, and timely
adjustment of the operating parameters if a variation in the
environment or input materials that would adversely impact
the drug product quality is detected.
Application of PAT involves four key components as
follows (40):
& Multivariate data acquisition and analysis
& Process analytical chemistry tools
& Process monitoring and control
& Continuous process optimization and knowledge
management
Multivariate data acquisition and analysis requires building
scientiﬁc understanding about a process and identifying critical
material attributes and process parameters that affect product
quality and integrating this knowledge into the process control,
which is essentially the same as the process understanding in the
context of QbD. Process analytical chemistry tools provide real-
time and in situ data about the status of the process. Multivariate
data analysis takes the raw information from the PAT tools and
connects it to CQAs. Based on the outcome of the data analysis,
process controls adjust critical variables to assure that CQAs are
met. The information collected about the process provides a basis
for further process optimization. Studies in FDA laboratories
indicated the promise of several PAT tools and chemometric
approaches (41–44).
CONCLUSION
The goals of implementing pharmaceutical QbD are to
reduce product variability and defects, thereby enhancing
product development and manufacturing efﬁciencies and
postapproval change management. It is achieved by designing
a robust formulation and manufacturing process and establish-
ing clinically relevant speciﬁcations. The key elements of
pharmaceutical QbD can include the QTPP, product design
and understanding, process design and understanding, and scale
up, control strategy, and continual improvement. Prior knowl-
edge, risk assessment, DoE, and PAT are tools to facilitate
QbD implementation. Finally, product and process capability is
assessed and continually improved postapproval during product
lifecycle management.
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